Abstract

Although current antipsychotic drugs are effective at treating the psychotic (positive) symptoms of schizophrenia, they have one or more serious side effects, including extrapyramidal symptoms, weight gain, cardiovascular liabilities and type II diabetes. However, recent data from clinical trials of selective neurokinin 3 (NK₃) receptor antagonists in schizophrenia ? osanetant and talnetant ? have shown significant improvement in positive symptoms, with no major side-effects reported as yet. Here we discuss the preclinical and clinical evidence that indicates that NK₃ receptor antagonists might represent a new approach to the treatment of schizophrenia and possibly other neuropsychiatric disorders.

Author affiliations

1. Will Spooren and Claus Riemer are at F. Hoffmann-La Roche, Pharmaceuticals Division, Psychiatry-Disease Area, Building 72-148, 4070 Basel, Switzerland.
2. Herbert Meltzer is at Psychiatric Hospital Vanderbilt, Suite 306 1601 23rd Avenue South, Nashville, Tennessee 37212, USA.

Correspondence to: Will Spooren¹ Email: will.spooren@roche.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.